Wolfgang Miesbach: The Growing Impact of Age-Related Disease in Hemophilia
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared post on LinkedIn:
“Crucial real-world data on our aging haemophilia population!
As life expectancy improves, our patients face new clinical challenges.
A massive Emory University analysis of US Medicare claims (2000-2020) looking at 2,058 adults (avg age 57.2; 1,735 Hem A or 323 Hem B) reveals critical shifts:
- Surging Comorbidities: Rates of arthropathy (the highest burden by far), liver disease, CVD, and renal disease are substantially higher in haemophilia patients vs. the matched US population.
- Elevated Mortality: Males with haemophilia face a 12% higher mortality rate (aHR is equal to 1.12) vs. the general public. (No significant difference in females: aHR is equal to 0.96).
- The Multiplier Effect: Having common chronic diseases (Cancer, COPD, CHF, CVD, Diabetes) drives a massive 67–300% increase in mortality rates for these patients.
We are managing the first true cohort of aging haemophilia patients. This data screams for a shift toward proactive, multidisciplinary prevention to tackle age-related chronic diseases alongside core bleeding risks.
Kudos to Stacey Fedewa, Christine Kempton, MD, MSc, and the Emory, Hemophilia of Georgia team for this excellent work!”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 16, 2026, 10:24Hichem Selatna: Advancing Hematology Laboratory Automation
-
Nov 16, 2026, 10:20Erin Harris: CRISPR Gene Therapy in Children
-
Nov 16, 2026, 10:19Beverley Hunt: PE Knows No Age – Isaac’s Story
-
Nov 16, 2026, 10:08Abdul Mannan: When Normal Blood Counts Hide Iron Deficiency
-
Nov 16, 2026, 09:47Ankit Kumar: A Memorable Experience at Haematocon 2026
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations